BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24979794)

  • 1. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
    Bhadury J; Nilsson LM; Muralidharan SV; Green LC; Li Z; Gesner EM; Hansen HC; Keller UB; McLure KG; Nilsson JA
    Proc Natl Acad Sci U S A; 2014 Jul; 111(26):E2721-30. PubMed ID: 24979794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
    Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
    Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression.
    Cummin TEC; Cox KL; Murray TD; Turaj AH; Dunning L; English VL; Fell R; Packham G; Ma Y; Powell B; Johnson PWM; Cragg MS; Carter MJ
    Blood Adv; 2020 Jul; 4(14):3316-3328. PubMed ID: 32717030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
    Derenzini E; Mondello P; Erazo T; Portelinha A; Liu Y; Scallion M; Asgari Z; Philip J; Hilden P; Valli D; Rossi A; Djaballah H; Ouerfelli O; de Stanchina E; Seshan VE; Hendrickson RC; Younes A
    Cell Rep; 2018 Aug; 24(8):2155-2166. PubMed ID: 30134175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
    Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
    Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
    Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.
    Muralidharan SV; Bhadury J; Nilsson LM; Green LC; McLure KG; Nilsson JA
    Oncogene; 2016 Sep; 35(36):4689-97. PubMed ID: 26804177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
    Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
    Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
    Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
    Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin C Sensitizes Melanoma to BET Inhibitors.
    Mustafi S; Camarena V; Volmar CH; Huff TC; Sant DW; Brothers SP; Liu ZJ; Wahlestedt C; Wang G
    Cancer Res; 2018 Jan; 78(2):572-583. PubMed ID: 29180474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Sun B; Fiskus W; Qian Y; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Saenz DT; Mill CP; Nowak AJ; Jain N; Zhang L; Wang M; Khoury JD; Coarfa C; Crews CM; Bhalla KN
    Leukemia; 2018 Feb; 32(2):343-352. PubMed ID: 28663582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
    Gusyatiner O; Bady P; Pham MDT; Lei Y; Park J; Daniel RT; Delorenzi M; Hegi ME
    Neuro Oncol; 2021 Oct; 23(10):1680-1692. PubMed ID: 33987681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
    Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
    J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
    Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
    Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
    Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR
    Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.